Skip to Content

Cerus Corp CERS

Morningstar Rating
$2.18 −0.02 (0.91%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CERS is trading at a 31% discount.
Price
$2.19
Fair Value
$2.93
Uncertainty
Very High
1-Star Price
$7.82
5-Star Price
$3.59
Economic Moat
Cmpd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CERS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.20
Day Range
$2.172.30
52-Week Range
$1.213.08
Bid/Ask
$2.18 / $2.25
Market Cap
$395.01 Mil
Volume/Avg
1.1 Mil / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2.57
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
309

Comparables

Valuation

Metric
CERS
TMDX
TELA
Price/Earnings (Normalized)
Price/Book Value
8.2719.515.41
Price/Sales
2.5711.042.74
Price/Cash Flow
85.14
Price/Earnings
CERS
TMDX
TELA

Financial Strength

Metric
CERS
TMDX
TELA
Quick Ratio
1.298.344.32
Current Ratio
1.889.305.36
Interest Coverage
−5.29−2.63−7.66
Quick Ratio
CERS
TMDX
TELA

Profitability

Metric
CERS
TMDX
TELA
Return on Assets (Normalized)
−12.63%−1.28%−50.85%
Return on Equity (Normalized)
−44.36%−4.30%−177.23%
Return on Invested Capital (Normalized)
−13.50%−1.70%−54.89%
Return on Assets
CERS
TMDX
TELA
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
ABT
Abbott LaboratoriesDjnjyq$208.3 Bil
SYK
Stryker CorpKrf$133.8 Bil
MDT
Medtronic PLCRpx$110.8 Bil
BSX
Boston Scientific CorpRgtmlw$98.3 Bil
EW
Edwards Lifesciences CorpGfjrswg$51.7 Bil
DXCM
DexCom IncBgnrx$44.0 Bil
ZBH
Zimmer Biomet Holdings IncSvtk$25.5 Bil
ALGN
Align Technology IncWfbqmyz$23.2 Bil
PHG
Koninklijke Philips NV ADRSxngz$18.2 Bil
SNN
Smith & Nephew PLC ADRPrnptr$11.6 Bil

Sponsor Center